08 July 2016
In this week’s EyewireTV, ReVision Optics receives FDA approval for the Raindrop Near Vision Inlay, the first implantable device that changes the shape of the cornea to achieve improved vision; and the FDA approves Humira (adalimumab) for the treatment of noninfectious intermediate and posterior uveitis and panuveitis. Also, Bausch + Lomb and Nicox announce that the results of a phase 3 study of glaucoma drug candidate latanoprostene bunod have been published in the American Journal of Ophthalmology.
07 July 2016
Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival. The test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.
30 June 2016
San Diego-based liquid biopsy company Epic Sciences has announced a new blood test that may quickly identify cancer patients who respond to a promising class of drugs called poly ADP ribose polymerase (PARP) inhibitors. The test works by identifying circulating tumor cells (CTCs) affected by homologous recombination deficiency (HRD), a damaged DNA repair mechanism.
28 June 2016
San Diego's Epic Sciences has added a new liquid biopsy test to its arsenal of biopharma cancer detection tools that targets homologous recombination deficiencies (HRDs) in individual circulating tumor cells.
09 June 2016
Presbyopia is an ocular condition associated with age related loss of near vision. The eye loses the ability to focus well on near objects due to the hardening of the natural lens. It affects billions of people worldwide with the onset occurring around age 45. The most common treatment for presbyopia is the use of reading glasses. Recently, surgical correction of presbyopia has been tested as part of a clinical study by implanting a small device into the cornea, the clear front part of the eye. The Raindrop Near Vision Inlay is an investigational device that is being evaluated to treat this condition so that dependence upon reading glasses may be reduced in order to see objects up close.
18 April 2016
Marinus Pharmaceuticals (NASDAQ:MRNS) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ganaxolone for the treatment of status epilepticus, according to the agency’s website. Status epilepticus is a dangerous condition in which epileptic seizures follow one another without recovery of consciousness between them.
16 March 2016
One test that could detect four of the most common sexually transmitted infections in 30 minutes and allow them to be rapidly treated, will be developed by St George’s, University of London and diagnostics company Atlas Genetics.
15 March 2016
The world’s largest nation, Russia remains an attractive market for most industries. Nevertheless, the country has struggled through a rough economic period, rocked by a drop in the value of the currency and turbulence in the oil market. Geopolitical pressures have raised challenges, including sanctions imposed on the country.
04 March 2016
Syndax ($SNDX) has joined a small group of biotechs that has managed to price an IPO in the face of gale force market headwinds. The biotech had to go well under its projected range, though, and settle for $12.
03 March 2016
Over the past year, Syndax Pharmaceuticals has altered its strategic course and hired new management to implement it. And it looks like that change was big enough to propel Waltham, MA-based Syndax through the IPO queue on its second attempt since late 2014—albeit not on the terms the company had hoped for.
12 September 2023
12 July 2023
21 March 2023
28 September 2023
28 September 2023
27 September 2023
27 September 2023